VEGFA and Pulmonary hemorrhage: Furthermore, the use of vascular endothelial growth factor (VEGF) inhibitors (eg, bevacizumab) has been demonstrated to be associated with an increased risk of fatal pulmonary hemorrhage in patients with SQC[12].